Literature DB >> 31304427

Pathology of pancreatic cancer.

Lena Haeberle1, Irene Esposito1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy and estimated to become the second leading cause of cancer-related deaths by 2030. Although overall 5-year survival rates have constantly remained below 10% for the last decades, several key points important for accurate patient stratification have emerged during recent years. These key points include a highly standardized gross examination of PDAC resection specimens, using an axial slicing technique and inking of the circumferential resection margin (CRM), as well as a meticulous microscopic examination, taking into account the prognostic relevance of factors such as the exact resection status (R0 vs. R1 1-mm vs. R1 resection), histopathological tumor grading and the so-called lymph node ratio (LNR). With increasing use of neoadjuvant therapy in PDAC, tumor regression grading (TRG) for PDAC is currently rising in relevance in order to stratify and manage pre-operatively treated PDAC patients. As all current TRG systems for PDAC are unsatisfactory, new standardized international protocols are urgently needed. Several morphological subtypes of PDAC exist, some of which share the same molecular background with classical PDAC, while others are characterized by a distinct molecular pathogenesis. While some show a prognosis similar to classical PDAC, other subtypes stand out due to a better or even worse prognosis than classical PDAC. Prognostic relevant molecular subtypes of PDAC have been proposed as well, however, limitations of used cohorts and the lacking correlation of molecular subtypes with histomorphological subtypes limit the translation of these findings into valuable clinical applications. Lastly, several macroscopic and microscopic precursor lesions of PDAC have been described in genetically engineered mouse models (GEMM) and humans in recent times, providing further insight into PDAC carcinogenesis. In addition, improved diagnosis of PDAC precursors represents a chance to select patients for resection before invasive PDAC is present.

Entities:  

Keywords:  Histomorphological variants; molecular subtypes; neoadjuvant treatment; pancreatic ductal adenocarcinoma (PDAC); precursor lesions; standardized pathology report

Year:  2019        PMID: 31304427      PMCID: PMC6624347          DOI: 10.21037/tgh.2019.06.02

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  37 in total

1.  Prognostic role of IRS-4 in the survival of patients with pancreatic cancer.

Authors:  Miguel A Ortega; Leonel Pekarek; Cielo Garcia-Montero; Oscar Fraile-Martinez; Miguel A Saez; Angel Asúnsolo; Miguel A Alvarez-Mon; Jorge Monserrat; Santiago Coca; M Val Toledo-Lobo; Natalio García-Honduvilla; Agustin Albillos; Julia Buján; Melchor Alvarez-Mon; Luis G Guijarro
Journal:  Histol Histopathol       Date:  2022-02-09       Impact factor: 2.303

Review 2.  Molecular signaling in pancreatic ductal metaplasia: emerging biomarkers for detection and intervention of early pancreatic cancer.

Authors:  Xiaojia Li; Jie He; Keping Xie
Journal:  Cell Oncol (Dordr)       Date:  2022-03-15       Impact factor: 6.730

Review 3.  The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.

Authors:  Cameron J Herting; Isaac Karpovsky; Gregory B Lesinski
Journal:  Cancer Metastasis Rev       Date:  2021-09       Impact factor: 9.264

Review 4.  Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.

Authors:  Mehran Taherian; Huamin Wang
Journal:  Chin Clin Oncol       Date:  2022-06-16

5.  Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer.

Authors:  Miguel A Ortega; Oscar Fraile-Martinez; Leonel Pekarek; Cielo García-Montero; Miguel Angel Alvarez-Mon; Alejandro J Castellanos; Natalio García-Honduvilla; Julia Buján; Melchor Alvarez-Mon; Miguel A Sáez; Luis G Guijarro; Angel Asúnsolo
Journal:  Antioxidants (Basel)       Date:  2022-04-11

6.  Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response.

Authors:  Yu Wang; Yiyi Liang; Haiyan Xu; Xiao Zhang; Tiebo Mao; Jiujie Cui; Jiayu Yao; Yongchao Wang; Feng Jiao; Xiuying Xiao; Jiong Hu; Qing Xia; Xiaofei Zhang; Xujun Wang; Yongwei Sun; Deliang Fu; Lei Shen; Xiaojiang Xu; Jing Xue; Liwei Wang
Journal:  Cell Discov       Date:  2021-05-25       Impact factor: 10.849

7.  GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first.

Authors:  Yi Tat Tong; Hua Wang; Dongguang Wei; Laura R Prakash; Michael Kim; Ching-Wei D Tzeng; Jeffrey E Lee; Asif Rashid; Eugene J Koay; Robert A Wolff; Anirban Maitra; Matthew Hg Katz; Huamin Wang
Journal:  Pancreatology       Date:  2021-08-18       Impact factor: 3.977

Review 8.  Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Authors:  Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 9.  Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool?

Authors:  Aleksandra Tarasiuk; Tomasz Mackiewicz; Ewa Małecka-Panas; Jakub Fichna
Journal:  Cancer Biol Ther       Date:  2021-07-05       Impact factor: 4.875

10.  The Dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in pancreatic and esophageal cancers.

Authors:  Hirokazu Kimura; Ryota Sada; Naoki Takada; Akikazu Harada; Yuichiro Doki; Hidetoshi Eguchi; Hideki Yamamoto; Akira Kikuchi
Journal:  Oncogene       Date:  2021-06-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.